LONDON (Alliance News) - Stem-cell therapy development company ReNeuron Group PLC Tuesday said data related to its exosome nanomedicine platform has been published in peer-reviewed scientific journal PLOS ONE.
The UK-based company is researching the "therapeutic potential of exosomes derived from its proprietary stem cell lines", as well as the potential of its exosomes as a delivery system for gene therapy treatments.
The publication follows news Monday the company had been awarded a GBP2.1 million grant from the government's Innovate UK initiative to further advance its exosome nanomedicine platform.
"This paper demonstrates the unique characteristic of our CTX cells to preferentially enrich a set of microRNAs contained within their exosomes, which we have shown to have anti-cancer properties in pre-clinical models. The paper therefore represents a significant milestone in ReNeuron's ongoing research to harness the potential of exosomes derived from its proprietary stem cell lines as therapeutics in their own right and also as a system for delivering therapeutic genes," said Chief Scientific Officer John Sinden in a statement.
Shares in ReNeuron Group were up 2.9% at 3.35 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)